Xiangxue Pharmaceutical Co.,Ltd.

Shenzhen Stock Exchange 300147.SZ

Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share for the year ending December 31, 2023: USD 0.04

Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share is USD 0.04 for the year ending December 31, 2023, a 243.99% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share for the year ending December 31, 2022 was USD -0.03, a 57.79% change year over year.
Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.07, a 30.73% change year over year.
Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -0.11, a 17.24% change year over year.
Xiangxue Pharmaceutical Co.,Ltd. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.13, a -35.70% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

Shenzhen Stock Exchange: 300147.SZ

Xiangxue Pharmaceutical Co.,Ltd.

CEO	Mr. Yonghui Wang
IPO Date	Dec. 15, 2010
Location	China
Headquarters	2 Jinfengyuan Road
Employees	2,644
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Vaccines

Description

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.

Key trends

Past 5 years